✦ LIBER ✦

290 A phase 2 study of pegylated interferon alfa-2B (peg-intron) for patients with metastatic renal cell carcinoma after removal of the primary tumour

✍ Scribed by A. Bex; M. Kerst; H. Mallo; S. Horenblas; G. De Gast

Book ID: 118645504
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 220 KB
Volume: 3
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(04)90290-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase-II study of pegylated interferon

A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor

✍ Axel Bex; Henk Mallo; Martijn Kerst; John Haanen; Simon Horenblas; Gijsbert C. d 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 207 KB

Infusional interleukin-2 and 5-fluoroura

Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma : A Southwest Oncology Group Phase II study

✍ Laurence Elias; Danika Lew; Robert A. Figlin; Robert C. Flanigan; Mark E. Thomps 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

Infusional interleukin-2 and 5-fluoroura

Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma: a Southwest Oncology Group phase II study.

✍ L Elias; D Lew; RA Figlin; RC Flanigan; ME Thompson; PL Triozzi; RJ Belt; DP Woo 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Interferon-α-2a with or without 13-cis r

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)

✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin

Randomized phase II/III trial of interfe

Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951): Aass N, De Mulder PHM, Mickisch GHJ, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ, Department of Clinical Cancer Research, The Norwegian Radium Hospital, Oslo, Norway

✍ Robert Flanigan 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 42 KB